Approval · Notice of Compliance 8332 · 2006
EXJADE: Notice of Compliance 8332
Issued October 18, 2006
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
Issued with conditions (NOC/c): the company must confirm the benefit in further studies.
- Notice number
- 8332
- Date
- October 18, 2006
- Company
- Novartis Pharmaceuticals Canada Inc.Montreal, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- New Drug Submission (NDS)
- Submission class
- Priority-NAS
- Therapeutic class
- Iron chelating agent
- With conditions
- Yes (NOC/c)
Products in this notice
Medicinal ingredients
- DEFERASIROX 125 MG per TAB
- DEFERASIROX 250 MG per TAB
- DEFERASIROX 500 MG per TAB